EPO Patents = 1

Trademarks = 1

Forward Citations = 0

Loading Chart...

9 inventors (with patents filed for the assignee):

David Stover (11 out of 13 patents)

Bruce Allan Hay (10 out of 27 patents)

Tahmineh Safaie (10 out of 10 patents)

4. Dhruba Bharali (10 out of 10 patents)

5. Alex Vasuthasawat (1 out of 4 patents)

6. Kham Trinh (1 out of 3 patents)

7. George Ayoub (1 out of 3 patents)

8. Sherie Morrison (1 out of 1 patent)

9. Tahmineh Safeie (0 patent)

11 patents: Sort by Forward Citations

1. 12702695 - Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof (2026-08-11),

2. 12653829 - Formulated and/or co-formulated compositions containing A2aR antagonist prodrugs useful in the treatment of cancer and methods thereof (2026-06-16),

3. 12311010 - Formulated and/or co-formulated liposome compositions containing toll-like receptor('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof (2025-05-27),

4. 12286403 - Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof (2025-04-29),

5. 12162958 - Fusion protein composition(s) comprising masked type i interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof (2024-12-10),

6. 12059470 - Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof (2024-08-13),

7. 11896646 - Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof (2024-02-13),

8. 11833209 - Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof (2023-12-05),

9. 11801304 - Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof (2023-10-31),

10. 11744874 - Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof (2023-09-05),

11. 11679141 - Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof (2023-06-20),

Company Overview

Nammi Therapeutics, Inc. is a biotechnology company based in Los Angeles, California, focused on developing innovative therapies for various medical conditions. The organization specializes in advanced drug delivery systems and novel therapeutic agents, leveraging cutting-edge research in molecular biology and pharmacology. With a commitment to improving patient outcomes, Nammi Therapeutics aims to address unmet medical needs through its pioneering approaches in therapeutic development and personalized medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

11 Patents

#181 in Los Angeles, CA

#6,544 in California

#27,529 in US

#51,801 in the World

Los Angeles, CA, United States of America

Nammi Therapeutics, Inc.

Forward Citations = 0

9 inventors:

David Stover (11 out of 13 patents)

Bruce Allan Hay (10 out of 27 patents)

Tahmineh Safaie (10 out of 10 patents)

4. Dhruba Bharali (10 out of 10 patents)

5. Alex Vasuthasawat (1 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nammi Therapeutics, Inc.. Retrieved from https://idiyas.com/company/nammi-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]